temozolomide has been researched along with Anorexia in 3 studies
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 9.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse." | 9.12 | [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 7.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 5.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse." | 5.12 | [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 3.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Elinzano, H | 1 |
| Toms, S | 1 |
| Robison, J | 1 |
| Mohler, A | 1 |
| Carcieri, A | 1 |
| Cielo, D | 1 |
| Donnelly, J | 1 |
| Disano, D | 1 |
| Vatketich, J | 1 |
| Baekey, J | 1 |
| Sturtevant, A | 1 |
| MacKinnon, K | 1 |
| Wood, R | 1 |
| Safran, H | 1 |
| Bae, SH | 1 |
| Park, MJ | 1 |
| Lee, MM | 1 |
| Kim, TM | 1 |
| Lee, SH | 1 |
| Cho, SY | 1 |
| Kim, YH | 1 |
| Kim, YJ | 1 |
| Park, CK | 1 |
| Kim, CY | 1 |
| Nishikawa, R | 1 |
| Shibui, S | 1 |
| Maruno, M | 1 |
| Sugiyama, K | 1 |
| Sato, S | 1 |
| Fujimaki, T | 1 |
| Takahashi, H | 1 |
| Wakabayashi, T | 1 |
| Takahashi, J | 1 |
| Kochi, M | 1 |
| Nakamura, H | 1 |
| Sawamura, Y | 1 |
| Ikeda, J | 1 |
| Hori, T | 1 |
| Aoki, T | 1 |
| Matsutani, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study[NCT03119064] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2017-11-30 | Terminated (stopped due to lack of response to study therapy) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. (NCT03119064)
Timeframe: Every two weeks for 4 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| All Participants | 50 |
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT03119064)
Timeframe: Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years.
| Intervention | participants (Number) | |
|---|---|---|
| Partial Response | Progressive Disease | |
| Dose 1 | 1 | 8 |
| Dose 2 | 1 | 2 |
Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4 (NCT03119064)
Timeframe: Baseline through 30 days post off study treatment
| Intervention | events (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | ALT/AST | Hypokalemia | Hypophosphatemia | Nausea | Fatigue | Diarrhea | Anorexia | Dehydration | Urticaria | |
| Dose 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 |
| Dose 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 0 |
2 trials available for temozolomide and Anorexia
| Article | Year |
|---|---|
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2006 |
1 other study available for temozolomide and Anorexia
| Article | Year |
|---|---|
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |